Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis
Read time: 2 mins
Last updated:13th Mar 2013
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.
|Date last updated at source||2016-09-13|
|Study start date||2013-03-13|
|Estimated primary completion date||2015-05-01|